Evidence map›Paper›PMID 36302947›Full record

ArticleScientific reports2022

Cardiopulmonary work up of patients with and without fatigue 6 months after COVID-19.

Kirsten Thiele, Paul Balfanz, Tobias Müller, Bojan Hartmann, Jens Spiesshoefer, Julian Grebe, Dirk Müller-Wieland, Nikolaus Marx, Michael Dreher, Ayham Daher

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Cardiovascular Symposium on Perspectives in Long COVID.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kirsten ThieleDepartment of Cardiology, Angiology and Intensive Care Medicine, University Hospital RWTH, 52074, Aachen, Germany.
Paul BalfanzDepartment of Cardiology, Angiology and Intensive Care Medicine, University Hospital RWTH, 52074, Aachen, Germany.
Tobias MüllerDepartment of Pneumology and Intensive Care Medicine, University Hospital RWTH, 52074, Aachen, Germany.
Bojan HartmannDepartment of Cardiology, Angiology and Intensive Care Medicine, University Hospital RWTH, 52074, Aachen, Germany.
Jens SpiesshoeferDepartment of Pneumology and Intensive Care Medicine, University Hospital RWTH, 52074, Aachen, Germany.
Julian GrebeDepartment of Cardiology, Angiology and Intensive Care Medicine, University Hospital RWTH, 52074, Aachen, Germany.
Dirk Müller-WielandDepartment of Cardiology, Angiology and Intensive Care Medicine, University Hospital RWTH, 52074, Aachen, Germany.
Nikolaus MarxDepartment of Cardiology, Angiology and Intensive Care Medicine, University Hospital RWTH, 52074, Aachen, Germany.
Michael DreherDepartment of Pneumology and Intensive Care Medicine, University Hospital RWTH, 52074, Aachen, Germany.
Ayham DaherDepartment of Pneumology and Intensive Care Medicine, University Hospital RWTH, 52074, Aachen, Germany. adaher@ukaachen.de.
RWTH Aachen University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pathogenesis of long-Covid symptoms remains incompletely understood. Therefore, we aimed to determine cardiopulmonary limitations 6 months after surviving COVID-19 using pulmonary function tests, echocardiographic studies to the point of analysis of global-longitudinal-strain (GLS), which describes the cycling myocardium deformation and provides better data on left ventricular (LV) dysfunction than LV ejection fraction (LVEF), and validated questionnaires. Overall, 60 consecutive hospitalized patients were included (61 ± 2 years, 40% treated in the ICU). At follow-up (194 ± 3 days after discharge), fatigue was the most prevalent symptom (28%). Patients with fatigue were more symptomatic overall and characterized by worse quality of life (QoL) scores compared to patients without fatigue (all p < 0.05), mainly due to limited mobility and high symptom burden. While PFT variables and LVEF were normal in the vast majority of patients (LVEF = 52% (45-52%)), GLS was significantly reduced (- 15% (- 18 to - 14%)). However, GLS values were not different between patients with and without fatigue. In conclusion, fatigue was the most prevalent long-Covid symptom in our cohort, which was associated with worse QoL mainly due to limited mobility and the high burden of concomitant symptoms. Patients showed a subtle myocardial dysfunction 6 months after surviving COVID-19, but this did not relate to the presence of fatigue.

Indexed as

COVID-19Ventricular Dysfunction, LeftFatigueHumansPost-Acute COVID-19 SyndromeQuality of LifeStroke VolumeVentricular Function, Left

Identifiers

PMID36302947
PMCPMC9607837
OpenAlexW4307777127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.